Article first published on PharmaTimes online 4thMay 2021
The COVID-19 pandemic has brought into question how we approach care across multiple disease areas in the future. But what does this mean in cancer? Hear from Bristol Myers Squibb’s (BMS) Executive Medical Director, Hubert Bland, who believes that in order to advance in cancer care, we must learn from the COVID-19 response and adopt a collaborative approach across the healthcare industry.
Over the last year, we have seen the strength and impact of clinical research, with the development of multiple COVID-19 vaccinations demonstrating how scientific collaboration can potentially tackle even the greatest challenges. We’ve also experienced the power of a pandemic, which has forced the healthcare industry to adopt flexible approaches to accelerate programmes that provide care fit for purpose under extreme pressure.
For cancer especially,